ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc. was founded in 2014 and is headquartered in California, USA. It is a clinical-stage biopharmaceutical company primarily focused on developing new therapies to address drug resistance in cancer cells, providing treatment options for patients with recurrent cancer. Although rapidly advancing targeted therapies have significantly improved patient outcomes, cancers often develop resistance to chemotherapy drugs, leaving relapsed patients with limited further treatment options. ORIC's co-founders, Dr. Charles Sawyers and Dr. Scott Lowe, lead a world-class oncology team dedicated to exploring novel cancer targets and developing innovative therapies to improve clinical outcomes for patients with recurrent cancer. ORIC’s lead candidate, ORIC-101, is a glucocorticoid receptor antagonist designed to counteract resistance to cancer therapeutics across various solid tumors. The drug is currently undergoing a Phase I clinical trial, where it is being tested in combination with chemotherapeutic agent Abraxane (NAB-paclitaxel), immune checkpoint inhibitors, and androgen receptor modulators used in prostate cancer treatment, to evaluate the safety and efficacy of ORIC-101.